论文部分内容阅读
目的探讨金匮肾气丸对2型糖尿病肾病大鼠胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)及血浆内皮素(endo-thelin,ET)的影响。方法抽取8只大鼠为空白组,其余均制备糖尿病肾病模型。选择造模成功的大鼠40只,随机分为模型组、罗格列酮组、金匮肾气大、中、小剂量组;各组给予相应干预措施共5周,检测空腹血糖(FBG)、尿白蛋白排泄率(UAER)、IGF-1及ET。结果各组给药后FBG较给药前明显降低,差异有统计学意义(P<0.05,P<0.01);各药物组FBG较模型组明显降低,差异有统计学意义(P<0.05,P<0.01);金匮肾气大剂量组与罗格列酮组血糖降低程度相当(P>0.05),金匮肾气中、小剂量组较金匮肾气大剂量组与罗格列酮组血糖差异有统计学意义(P<0.01)。与模型组比较,各药物组UAER降低,差异有统计学意义(P<0.05,P<0.01);IGF-1升高,ET降低,差异有统计学意义(P<0.01)。金匮肾气各剂量组与罗格列酮组比较,IGF-1差异无统计学意义,ET除金匮肾气小剂量组外(P<0.05),金匮肾气大、中剂量组差异无统计学意义(P>0.05)。与金匮肾气大剂量组比较,中、小剂量组UAER差异有统计学意义(P<0.05,P<0.01);与金匮肾气小剂量组比较,大、中剂量组ET差异有统计学意义(P<0.01)。结论金匮肾气丸可以降低2型糖尿病肾病大鼠FBG、UAER、ET,升高IGF-1,从而起到防治糖尿病肾病的作用。
Objective To investigate the effect of Jinkuishenqi Pill on insulin-like growth factor-1 (IGF-1) and endothelin (ET) in type 2 diabetic nephropathy rats. Methods Eight rats were selected as the blank group, and the rest were all prepared diabetic nephropathy model. Forty rats with successful modeling were randomly divided into model group, rosiglitazone group and Jing Kui Shen Qi large, middle and small dose groups, and the corresponding interventions were given for 5 weeks in each group. The levels of fasting blood glucose (FBG) , Urinary albumin excretion rate (UAER), IGF-1 and ET. Results The FBG in each group was significantly lower than that before treatment (P <0.05, P <0.01). FBG in each drug group was significantly lower than that in model group (P <0.05, P <0.01). The blood glucose level of Jingui Shenqi high-dose group and rosiglitazone group was similar (P> 0.05). The effect of Jingui Shenqi medium and low-dose group was significantly lower than that of Jingui Shenqi high-dose group and rosiglitazone group Blood glucose differences were statistically significant (P <0.01). Compared with the model group, the UAER in each drug group decreased, the difference was statistically significant (P <0.05, P <0.01); IGF-1 increased, ET decreased, the difference was statistically significant (P <0.01). There was no significant difference in the IGF-1 levels between each dose of Jinkui Shenqi and rosiglitazone groups, except for the low dose of Jingui Shenqi (P <0.05) No statistical significance (P> 0.05). Compared with the Jingui Shenqi high-dose group, UAER in the middle-small dose group was significantly different (P <0.05, P <0.01); Compared with Jingui Shenxuan low-dose group, Significance (P <0.01). Conclusion Jinkuishenqi Pill can reduce FBG, UAER and ET in type 2 diabetic nephropathy rats and increase IGF-1, thus playing a role in prevention and treatment of diabetic nephropathy.